title: Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: role of infusion schedule and costimulation with cytokines.
abstract: The natural killer cell-activating anti-CD16/CD30 bispecific monoclonal antibody (BiMAb) had shown efficacy in a Phase I/II trial of refractory Hodgkin's disease (HD). To gain additional information on clinical efficacy and to investigate the effects of different application schedules and the concomitant application of cytokines, we performed a second randomized pilot trial using this BiMAb in patients with refractory HD. Patients received 4 x 25 mg HRS-3/A9 either as a continuous infusion for 4 days or as a 1-h infusion every other day. In case of an objective response, retreatment was attempted after 4 weeks; in case of stable disease (SD), a second course was given after prestimulation with interleukin 2 and followed by granulocyte macrophage colony-stimulating factor s.c. A total of 16 heavily pretreated patients received one to four BiMAb courses. Overall, we observed one complete remission and three partial remissions lasting 5-9 months (three of four of these responses occurred after continuous BiMAb infusion) and four cases of SD for 3 to >6 months. Interleukin 2 pretreatment before the second BiMAb course resulted in a significant increase of circulating natural killer cells in all five patients treated. This coincided with the conversion of two cases of SD into one complete remission and one partial remission. HRS-3/A9-related side effects consisted of mild fever in only six patients. In summary, this second trial confirmed the antitumor efficacy of this BiMAb against HD and the minor toxicity of this BiMAb. Coadministration of cytokines might contribute to an augmented antitumor activity, and additional clinical trials are warranted to optimize this novel treatment modality.
authors.affiliation: Department of Medicine, Saarland University Medical School D-66421 Homburg, Germany.
authors.forename: F
authors.initials: F
authors.lastname: Hartmann
authors.forename: C
authors.initials: C
authors.lastname: Renner
authors.forename: W
authors.initials: W
authors.lastname: Jung
authors.forename: L
authors.initials: L
authors.lastname: da Costa
authors.forename: S
authors.initials: S
authors.lastname: Tembrink
authors.forename: G
authors.initials: G
authors.lastname: Held
authors.forename: A
authors.initials: A
authors.lastname: Sek
authors.forename: J
authors.initials: J
authors.lastname: König
authors.forename: S
authors.initials: S
authors.lastname: Bauer
authors.forename: M
authors.initials: M
authors.lastname: Kloft
authors.forename: M
authors.initials: M
authors.lastname: Pfreundschuh
mesh_terms: D000328:Adult; D018033:Antibodies, Bispecific / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D005334:Fever / Q000139:chemically induced; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007260:Infusion Pumps; D007376:Interleukin-2 / Q000008:administration & dosage; D017730:Ki-1 Antigen / Q000276:immunology*; D007958:Leukocyte Count; D018655:Lymphocyte Count; D016131:Lymphocyte Subsets / Q000166:cytology / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000166:cytology / Q000187:drug effects; D010865:Pilot Projects; D017452:Receptors, IgG / Q000276:immunology*; D016896:Treatment Outcome
chemical_list: D018033:Antibodies, Bispecific; D000911:Antibodies, Monoclonal; D007376:Interleukin-2; D017730:Ki-1 Antigen; D017452:Receptors, IgG